dc.contributor.author |
Maurya, Ranjani |
|
dc.contributor.author |
Soni, Awakash |
|
dc.contributor.author |
Anand, Devireddy |
|
dc.contributor.author |
Ravi, Makthala |
|
dc.contributor.author |
Raju, K S R |
|
dc.contributor.author |
Taneja, Isha |
|
dc.contributor.author |
Naikade, N K |
|
dc.contributor.author |
Puri, S K |
|
dc.contributor.author |
Wahajuddin |
|
dc.contributor.author |
Kanojiya, Sanjeev |
|
dc.contributor.author |
Yadav, P P |
|
dc.date.accessioned |
2013-03-06T06:27:38Z |
|
dc.date.available |
2013-03-06T06:27:38Z |
|
dc.date.issued |
2013 |
|
dc.identifier.citation |
ACS Medicinal Chemistry Letters, 2013, 4 (2), 165–169 |
en |
dc.identifier.uri |
http://hdl.handle.net/123456789/1008 |
|
dc.description.abstract |
Novel 3,3-spiroanellated 5-aryl, 6-arylvinyl substituted 1,2,4-trioxanes 19-34 have been syn-thesized and appraised for their antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in swiss mice by oral route at the doses ranging from 96 mg/kg x 4 days to 24 mg/kg x 4 days. 1,2,4-trioxane 25 the most active compounds of the series, provided 100% protection at 24 mg/kg x 4 days and other 1,2,4-trioxanes 22, 26, 27 and 30 also showed promising activity. In this model β-arteether provided 100% and 20% protection at 48 mg/kg x 4 days and 24 mg/kg x 4 days, respectively by oral route. |
en |
dc.format.extent |
232406 bytes |
|
dc.format.mimetype |
application/pdf |
|
dc.language.iso |
en |
en |
dc.relation.ispartofseries |
CDRI communication no. 8341 |
en |
dc.subject |
1,2,4-trioxane |
en |
dc.subject |
Antimalarial |
en |
dc.subject |
In-vivo |
en |
dc.subject |
Orally active |
en |
dc.title |
Synthesis and Antimalarial activity of 3,3-spiroanellated 5,6-disubstituted-1,2,4-trioxanes |
en |
dc.type |
Article |
en |